Dr. Zoya N. Demidenko

Zoya N. Demidenko, Ph.D. is Executive Manager of the Oncotarget journal.
 
Oncotarget publishes high-impact research papers of general interest and outstanding significance and novelty in all areas of biology and medicine: in translational, basic and clinical research including but not limited to cancer research, oncogenes, oncoproteins and tumor suppressors, signaling pathways as potential targets for therapeutic intervention, shared targets in different diseases (cancer, benign tumors, atherosclerosis, eukaryotic infections, metabolic syndrome and other age-related diseases), chemotherapy, and new therapeutic strategies.
 
After earning her Ph.D. in molecular biology, Zoya was awarded a Fogarty post-doctoral Fellowship from the National Institutes of Health in Bethesda, MD. After successful completion of post-doctoral training, she continued her professional career at George Washington University and Albert Einstein School of Medicine.
 
In 2005 she cofounded the startup company Oncotarget Inc. which is focused on the development of anti-aging and anti-cancer drugs. Her research interests include signal transduction, cell cycle and cellular senescence, and their pharmacological targeting. In 2009 she cofounded the publishing house Impact Journals which specializes in publishing scientific journals. In 2011 she was selected to be a Member of the National Association of Professional Women.
 
Her papers include The Regulation of Hypoxic Genes by Calcium Involves c-Jun/AP-1, Which Cooperates with Hypoxia-Inducible Factor 1 in Response to Hypoxia, Growth stimulation leads to cellular senescence when the cell cycle is blocked, Rapamycin decelerates cellular senescence, Paradoxical suppression of cellular senescence by p53, Paclitaxel Induces Primary and Postmitotic G₁ Arrest in Human Arterial Smooth Muscle Cells, Inhibition of Transcription Results in Accumulation of Wt p53 Followed by Delayed Outburst of p53-Inducible Proteins: p53 as a Sensor of Transcriptional Integrity, and At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence.